Brokerages Set United Therapeutics Corporation (NASDAQ:UTHR) Target Price at $619.42

United Therapeutics Corporation (NASDAQ:UTHR) has been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $619.4167.

UTHR has been the subject of several recent analyst reports. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Royal Bank Of Canada reduced their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company.

Insider Activity

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 14,440 shares of United Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 542,113 shares of company stock valued at $301,914,315. 8.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its stake in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares during the last quarter. Bull Harbor Capital LLC bought a new stake in United Therapeutics during the first quarter worth about $494,000. Strategic Investment Advisors MI lifted its stake in United Therapeutics by 20.5% during the first quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock worth $5,782,000 after purchasing an additional 1,662 shares during the last quarter. Talon Private Wealth LLC bought a new stake in United Therapeutics during the first quarter worth about $3,038,000. Finally, Royal Bank of Canada lifted its stake in United Therapeutics by 3.3% during the first quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company’s stock worth $35,075,000 after purchasing an additional 1,864 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $563.93 on Thursday. The stock has a market cap of $23.94 billion, a PE ratio of 20.82, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. United Therapeutics has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The stock has a fifty day moving average of $562.18 and a 200-day moving average of $510.32.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the firm earned $6.63 earnings per share. United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts predict that United Therapeutics will post 27.07 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.